Takeda Pharmaceutical Co. Ltd. 4502

WASHINGTON & TOKYO, October 01, 2026--Corus International announced it has received a $6.4 million grant from Takeda Pharmaceutical Company Limited to help reduce climate-related health risks in Nepal. Corus was selected as part of Takeda’s 2026 Global Corporate Social Responsibility (CSR) program. The company issued a press release announcing all the awardees and the scope of its program.

Takeda Pharmaceutical recently reported Phase 3 data showing that its investigational oral TYK2 inhibitor, zasocitinib (TAK-279), achieved statistically superior complete skin clearance versus deucravacitinib and outperformed apremilast in adults with moderate-to-severe plaque psoriasis, with results presented at the 2026 European Academy of Dermatology & Venereology Congress. A particularly important finding is that zasocitinib delivered more than 2.5 times as many patients with complete...

Takeda Pharmaceutical (TSE:4502) has put its psoriasis pipeline in the spotlight after new Phase 3 LATITUDE data showed that investigational pill zasocitinib outperformed deucravacitinib on skin clearance measures in adults with moderate to severe plaque psoriasis. Taken together with Takeda Pharmaceutical’s oncology pipeline updates and recent leadership change in Spain, the psoriasis data arrives during a period of strong market performance, with the share price up 17.6% year to date and a...

Asian equities traded in the US as American depositary receipts were tracking modestly higher Wednes

Takeda (TAK) said Wednesday that its experimental pill zasocitinib showed superior results compared

OSAKA, Japan & CAMBRIDGE, Mass., September 30, 2026--Takeda (TSE:4502/NYSE:TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis.1 Presented during late-breaking and oral sessions at the European Academy of Dermatology & Venereology (EADV) Congress 2026, these results demonstrate zasocitinib’s superi

Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.

BOSTON, September 29, 2026--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic diseases, announces expansion of the global Phase 3 MarsLight-11 (NCT07217301) trial, which is evaluating IBI363 (Takeda R&D code: TAK-928) in patients with squamous non-small cell lung cancer (NSCLC) whose disease has progressed on or after chemo

Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Another big AI haul Investors are still lining up to back AI drug developers before their candidates reach human trials. Basecamp Research...

OSAKA, Japan & CAMBRIDGE, Mass., September 22, 2026--Takeda (TSE:4502/NYSE:TAK) announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (briga

Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy as competition intensifies.

OSAKA, Japan & CAMBRIDGE, Mass., September 18, 2026--Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to supporting climate-resilient health systems in low- and middle-income countries around the world and aligned with the company’s purpose of better health for people, brighter future for the world. As climate change, extreme weather events and shifti

Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on September 14 that the FDA accepted its New Drug Application for zasocitinib under priority review for adults with moderate-to-severe plaque psoriasis. The target action date falls in the first quarter of calendar 2027, creating a defined regulatory window for the investigational once-daily oral treatment. Zasocitinib inhibits tyrosine kinase […]

Earlier this month, Novavax participated in investor-focused healthcare conferences hosted by Citigroup and Cantor Fitzgerald in New York, outlining its vaccine and partnership positioning to a broad institutional audience. Around the same time, bipartisan lawmakers introduced the Protecting Approved Care Act, stirring concern across healthcare names like Novavax about potential changes to Medicare Advantage reimbursement practices and administrative requirements. We’ll now examine how...

Recently published Myelodysplastic Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, myelodysplastic syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Experienced life sciences executive brings more than two decades of global drug development, commercialization and business development experience SINGAPORE, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Hummingbird Bioscience (“Hummingbird”), a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet need, today announced the appointment of Dr. James Garner as President. Dr. Garner will join Hummingbird Bioscience’s leadership team and work alongside

Asian equities traded in the US as American depositary receipts started the trading week heading sha

SIG, TAK and TX made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 14th, 2026.

TX, HPQ and TAK made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 14th, 2026.